Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 20/20 | 0.53 |
| ▸ | PTGDR | Q13258 | 10/20 | 0.53 |
| ▸ | TBXA2R | P21731 | 9/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3090467 | 0.92 | PTGDR2 (0.54) | PTGDR2PTGDRTBXA2RCYP2C9CYP3A4 | |
| SCHEMBL3083458 | 0.87 | PTGDR2 (0.54) | PTGDR2PTGDRTBXA2RCYP2C9CYP3A4 | |
| SCHEMBL3089889 | 0.87 | PTGDR2 (0.53) | PTGDR2PTGDRTBXA2RCYP2C9CYP3A4 | |
| SCHEMBL204983 | 0.87 | PTGDR2 (0.53) | PTGDR2PTGDRTBXA2RCYP2C9CYP3A4 | |
| SCHEMBL3085507 | 0.81 | PTGDR2 (0.49) | PTGDR2PTGDRTBXA2RCYP2C9 | |
| SCHEMBL3084600 | 0.80 | PTGDR2 (0.46) | PTGDR2PTGDRTBXA2RCYP2C9 | |
| SCHEMBL3099692 | 0.80 | PTGDR2 (0.46) | PTGDR2PTGDRTBXA2RCYP2C9 | |
| SCHEMBL3091558 | 0.79 | PTGDR2 (0.54) | PTGDR2PTGDRTBXA2RCYP2C9CYP3A4 | |
| SCHEMBL3090536 | 0.78 | PTGDR2 (0.49) | PTGDR2PTGDRTBXA2RCYP2C9 | |
| SCHEMBL15445016 | 0.78 | PTGDR2 (0.55) | PTGDR2PTGDRTBXA2RCYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9023864-B2 | Indole derivatives as CRTH2 receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-05-05 | — | — | US | disclosed |
| US-9023864-B2 | Indole derivatives as CRTH2 receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20130150398-A1 | Indole Derivatives as CRTH2 Receptor Antagonists | MERCK SHARP & DOHME LLC | 2013-06-13 | — | — | US | disclosed |
| US-20130150398-A1 | Indole Derivatives as CRTH2 Receptor Antagonists | MERCK SHARP & DOHME LLC | 2013-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150398-A1 | Indole Derivatives as CRTH2 Receptor Antagonists | PTGER2, PTGDR2, PTGDR | PTGDR2 2/4885PTGDR 3/4885TBXA2R 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.